Loading...
•
Sep 30
OrthoPediatrics Q3 2025 Earnings Report
OrthoPediatrics reported its third quarter 2025 financial results, with increased revenue and adjusted EBITDA year-over-year.
Key Takeaways
OrthoPediatrics delivered a strong third quarter in 2025, achieving record high total revenue of $61.2 million, a 12% increase year-over-year. The company also significantly improved its adjusted EBITDA by 56% to $6.2 million and reduced free cash flow usage by $8.2 million. Despite a GAAP diluted loss per share of $(0.50), the company saw robust growth in its Trauma & Deformity and Scoliosis segments, driven by strategic initiatives and new product approvals.
Total revenue reached a record high of $61.2 million, up 12% from the prior year.
Adjusted EBITDA increased by 56% to $6.2 million, demonstrating improved profitability.
Free cash flow usage improved by $8.2 million, indicating better cash management.
Worldwide Trauma & Deformity revenue grew 17% and Scoliosis revenue grew 4%.
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Revenue by Segment
Trauma and Deformity Revenue
CapyFin.comScoliosis Revenue
CapyFin.comSports Medicine/Other Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
OrthoPediatrics updated its full-year 2025 revenue guidance to a range of $233.5 million to $234.5 million, representing 14% to 15% growth over 2024. The company also reiterated its annual set deployment at $15.0 million and adjusted EBITDA guidance of $15.0 million to $17.0 million for the full year.
Positive Outlook
- Full year 2025 revenue guidance reflects strong growth of 14% to 15%.
- Reiterated annual set deployment of $15.0 million.
- Reiterated adjusted EBITDA guidance of $15.0 million to $17.0 million for the full year.
- Focus on strong execution of strategic initiatives including scaling OPSB.
- Leveraging prior set deployments and introducing innovative new products.
Challenges Ahead
- 7D capital sales did not meet expectations.
- Latin and South America revenue did not meet expectations.
- Decline in 7D unit sales impacted overall revenue growth.
- Lower stocking and set sales to Latin and South America.
- No specific negative adjustments to full-year guidance were provided beyond the initial Q3 performance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income